Aug 21 (Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
clinical trial evaluating the safety and efficacy of Baxter International 's ( BAX +0.9% ) BAX 855 , an extended half-life recombinant factor ..... on-demand group (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes
Baxter has reported positive ..... Phase III study of BAX 855, a twice-weekly ..... particularly given that BAX 855 is now one step ..... committee review of Baxter 's differentiated ..... for the stock. Baxter 's wide, stable ..... patients taking BAX 855 as a twice-weekly
directors have deep experience in the international pharmaceuticals industry, while the remaining directors have a range ..... of the three biggest industry players, along with Baxter International of the U.S. and Grifols of Spain. These three
By Northport Investments : Baxter International (NYSE: BAX ) is a company that is entering ..... safe stock" without any risk, BAX shares are relatively safe in comparison ..... portfolio. With the split of BAX into 2 companies approaching in
However, there are underlying risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen
all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy ..... jucier margins in return. Deep-pocketed partners Baxter (NYSE: BAX ) and Novartis (NYSE: NVS ) are eager to exploit
The U.S. regulator approves Baxter International 's ( BAX -1% ) Flexbumin 5% Solution indicated for hypovolemia , hypoalbuminemia due to general causes, burns and in patients undergoing
June I wrote a bullish article on Baxter (NYSE: BAX ), with a thesis stating that the ..... also stated that the expansion of Baxter 's ADVATE program into emerging ..... there are underlying risks to a Baxter investment, given that the company
WASHINGTON, July 31 (Reuters) - The benefit of Baxter International Inc 's experimental immune deficiency therapy, HyQvia, outweighs the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday.